This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).

No content found

Data pager
Data pager
12
 Item 1 to 99 of 138
of 2 
Show all 138
Data pager
Data pager
12
 Item 1 to 99 of 138
of 2 
Show all 138
Friday, March 27 | 3:00PM - 7:30PM
Registration
Room: Foyer


Friday, March 27 | 6:30PM - 7:30PM
Refreshments
Room: Foyer


Friday, March 27 | 7:30PM - 8:30PM
Keynote Address (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 1 of 3
* James D. Marks, University of California, San Francisco, USA

Friday, March 27 | 7:30PM - 8:30PM
Keynote Address (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 2 of 3
* Barbara L. Weber, Tango Therapeutics, USA

Friday, March 27 | 7:30PM - 8:30PM
Keynote Address (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 3 of 3
David P. Lane, Agency for Science, Technology and Research, Singapore
Target Validation in Cancer Treatment: The Use of Chemical Biology and Protein Aptamer Approaches

Saturday, March 28 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky Ballroom A, Lower Level


Saturday, March 28 | 7:00AM - 8:00AM
Poster Setup
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 1 of 8
* James E. Bradner, Novartis Institutes for BioMedical Research, USA

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 2 of 8
* James D. Marks, University of California, San Francisco, USA

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 3 of 8
Andreas G. Plückthun, University of Zürich, Switzerland
Ankyrin Repeat Proteins

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 4 of 8
Nick Terrett, Ensemble Discovery Corporation, USA
A DNA-Programmed Chemistry Approach to Macrocyclic Lead Compounds

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 5 of 8
Gregory L. Verdine, Harvard University, USA
Drugging “Undruggable” Targets Using Stapled Peptides

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 6 of 8
Rodney W. Lappe, CovX Research LLC, Pfizer, USA
Using CovX-Body Technology to Target the Angiopoietin Axis

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 7 of 8
Yollete V. Guillen Schlippe, Massachusetts General Hospital, USA
Short Talk: Selection of Cyclic Peptides Composed of Multiple Unnatural Amino Acids that Display Antibody-Like Affinity

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 8 of 8
Jennifer R. Cochran, Stanford University, USA
Short Talk: Engineered Knottin Peptides: A New Class of Agents for Imaging Integrin Expression in Living Subjects

Saturday, March 28 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Saturday, March 28 | 11:15AM - 12:00PM
Lunch
Room: Foyer/Sea to Sky Ballroom A


Saturday, March 28 | 12:00PM - 2:30PM
Poster Session 1
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 1 of 6
* Louis M. Weiner, Georgetown University Medical Center, USA

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 2 of 6
Steve K. Horrigan, Avalon Pharmaceuticals, USA
Systems Biology for Lead Optimization

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 3 of 6
Lutz Jermutus, MedImmune LLC, UK
Discovering Cancer Therapeutics by Phage and Ribosome Display as well as Transgenics Technologies

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 4 of 6
Ravi Majeti, Stanford University, USA
Blocking Monoclonal Antibodies Directed Against CD47 Preferentially Enable Phagocytosis and Elimination of Human Acute Myeloid Leukemia Stem Cells

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 5 of 6
Teemu T. Junttila, Genentech, Inc., USA
Superior in vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2 Amplified Breast Cancer

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 6 of 6
Mariia Yuneva, Francis Crick Institute, UK
Combining Metabolomics with Microarray Analysis to Determine Metabolic Cancer Targets in vivo

Saturday, March 28 | 4:30PM - 5:00PM
Coffee Available
Room: Foyer


Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
Room: Sea to Sky Ballroom B

Speaker 1 of 5
* Lutz Jermutus, MedImmune LLC, UK

Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
Room: Sea to Sky Ballroom B

Speaker 2 of 5
George Georgiou, University of Texas at Austin, USA
Selection, Fc Engineering and Preparative Expression of Full Length IgG in E.coli

Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
Room: Sea to Sky Ballroom B

Speaker 3 of 5
James D. Marks, University of California, San Francisco, USA
Selecting Internalizing Antibodies for Drug Delivery

Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
Room: Sea to Sky Ballroom B

Speaker 4 of 5
Max Woisetschlager, F-Star, Austria
Antigen Binding by Modified Immunoglobulin Fc (Fcab) and Complete IgGs with Additional Binding Sites

Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
Room: Sea to Sky Ballroom B

Speaker 5 of 5
Roger R. Beerli, NBE-Therapeutics AG, Switzerland
Short Talk: Isolation and Preclinical Validation of Therapeutic Human Monoclonal Antibodies Isolated by Mammalian Cell Display

Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 1 of 6
* Gregory L. Verdine, Harvard University, USA


Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 2 of 6
James E. Bradner, Novartis Institutes for BioMedical Research, USA
Next-Generation Histone Deacetylase Inhibitors


Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 3 of 6
Saul H. Rosenberg, Abbott Laboratories, USA
Targeting Apoptosis: Bcl-2 Family Protein Inhibitors


Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 4 of 6
Nathanael Gray, Stanford University, USA
Tackling the Kinome: Bcr-Abl, EML4-ALK in EGFR


Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 5 of 6
Kathlynn C. Brown, University of Texas Southwestern Medical Center, USA
Short Talk: Isolation of a Suite of Cell Binding Peptides: Novel Ligands for Diagnosis and Targeted Therapy for Non-Small Cell Lung Cancer


Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 6 of 6
Suzanne Forry-Schaudies, National Cancer Institute, National Institutes of Health, USA
Short Talk: NCI Chemical Biology Consortium (CBC)


Saturday, March 28 | 7:00PM - 7:00PM
On Own for Dinner


Sunday, March 29 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky Ballroom A, Lower Level


Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
Room: Sea to Sky Ballroom B

Speaker 1 of 7
* Raphael Clynes, Xencor, Inc., USA

Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
Room: Sea to Sky Ballroom B

Speaker 2 of 7
Louis M. Weiner, Georgetown University Medical Center, USA
Optimizing in vitro and in vivo ADCC for Cancer Therapy

Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
Room: Sea to Sky Ballroom B

Speaker 3 of 7
John R. Desjarlais, Xencor, Inc., USA
Engineered Fc Domains for Enhanced Cytotoxicity and Pharmacokinetics

Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
Room: Sea to Sky Ballroom B

Speaker 4 of 7
Pablo Umaña, Roche Innovation Center Zürich, Switzerland
New Glycoengineered Antibodies with Enhanced Effector Functions

Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
Room: Sea to Sky Ballroom B

Speaker 5 of 7
E. Sally Ward, University of Texas Southwestern Medical Center, USA
The Role of FcRn in IgG Homeostasis: Implications for the Use of Antibodies in Therapy

Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
Room: Sea to Sky Ballroom B

Speaker 6 of 7
Jeanette H.W. Leusen, University Medical Center Utrecht, Netherlands
Short Talk: The Fc Receptor gamma-Chain ITAM is Required for Antibody Immunotherapy

Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
Room: Sea to Sky Ballroom B

Speaker 7 of 7
Shu-ichi Hashimoto, Chiome Bioscience Inc., Japan
Short Talk: ADLib System: New Antibody Generating Technology based on Cell Surface Displayed Antibody Library

Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 1 of 7
* Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA


Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 2 of 7
Craig B. Thompson, Memorial Sloan Kettering Cancer Center, USA
Mitochondrial Targets


Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 3 of 7
Pierre Sonveaux, University of Louvain, Belgium
Lactate-Fueled Tumor Cell Respiration: A New Paradigm and a New Target for Therapy


Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 4 of 7
Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA
Role of Feedback and Redundancy in Oncoprotein Activated Signaling Pathways


Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 5 of 7
D. Gary Gilliland, Merck & Co., Inc., USA
Genome Wide shRNA-Based Synthetic Lethality Screens to Target 'Undruggable' Cancer Disease Alleles


Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 6 of 7
Daniel Monticello, Molecular Logix Inc, USA
Short Talk: Development of a Pan-HER Dominant Negative Ligand that Inhibits HER Phosphorylation and HER-Ligand Dependent Tumor Cell Growth


Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 7 of 7
Peter R. Rhode, Altor BioScience Corp., USA
Short Talk: IL-15 Superagonist as a Targeted Immunotherapeutic Molecule


Sunday, March 29 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Sunday, March 29 | 11:15AM - 11:15AM
On Own for Lunch


Sunday, March 29 | 11:15AM - 1:00PM
Poster Setup
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Sunday, March 29 | 1:00PM - 10:00PM
Poster Viewing
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 1 of 8
* James D. Marks, University of California, San Francisco, USA

Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 2 of 8
Robert Mabry, ZymoGenetics, Inc., USA
Selection of Stable Antibody Fragments for Assembly of Dual-Targeting Therapeutics

Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 3 of 8
Carston R. Wagner, University of Minnesota, USA
Chemically Controlled Assembly of Single-Chain Antibody Nanorings

Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 4 of 8
Wei Yan, Amgen Inc., USA
Design and Engineering of Fc Heterodimers for the Production of Bispecific Antibodies

Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 5 of 8
Aran Frank Labrijn, Genmab, Netherlands
Therapeutic IgG4 Antibodies Engage in Fab-Arm Exchange with Patient’s IgG4 in vivo

Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 6 of 8
Ann P. MacLaren, Biogen Idec, USA
A Novel Tetravalent Anti-CD23 Antibody Induces Potent Anti-Tumor Activity in CD23+ Tumor Cells via Hyper Cross-Linking of CD23

Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 7 of 8
Klaus Koefoed, Symphogen A/S, Denmark
Development of Sym004 - a Dual Antibody Combination Targeting the Epidermal Growth Factor Receptor with Strong Anti-Tumor Efficacy in a Xenograft Mouse Model

Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
Room: Sea to Sky Ballroom B

Speaker 8 of 8
Rob Roovers, Merus BV, Netherlands
Combining Different Modes of EGFR Inhibition into a Single Nanobody-Based Molecule Yields a Promising Anti-Cancer Drug

Sunday, March 29 | 4:30PM - 5:00PM
Coffee Available
Room: Foyer


Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
Room: Sea to Sky Ballroom B

Speaker 1 of 5
* E. Sally Ward, University of Texas Southwestern Medical Center, USA

Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
Room: Sea to Sky Ballroom B

Speaker 2 of 5
Raphael Clynes, Xencor, Inc., USA
Conversion of Passive Antibody Therapy to Active Immunity

Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
Room: Sea to Sky Ballroom B

Speaker 3 of 5
Gerard Zurawski, Baylor Institute for Immunology Research, USA
Vaccines Based on Targeting Antigens Directly to DCs

Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
Room: Sea to Sky Ballroom B

Speaker 4 of 5
Kavita Dhodapkar, Emory University, USA
Antibody-Based Induction of Adaptive Immune Response

Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
Room: Sea to Sky Ballroom B

Speaker 5 of 5
Mark S. Cragg, University of Southampton, UK
Short Talk: The Role of Activatory and Inhibitory FcgR in Antibody Immunotherapy

Sunday, March 29 | 5:00PM - 7:00PM
Autophagy and Metabolism
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 1 of 3
Matthew G. Vander Heiden, Massachusetts Institute of Technology, USA
Targeting Cancer Cell Metabolism


Sunday, March 29 | 5:00PM - 7:00PM
Autophagy and Metabolism
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 2 of 3
Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA
Targeting Energy Sensing


Sunday, March 29 | 5:00PM - 7:00PM
Autophagy and Metabolism
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 3 of 3
Chi Van Dang, University of Pennsylvania, USA
Therapeutic Implications of the Warburg Effect


Sunday, March 29 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Sunday, March 29 | 7:30PM - 10:00PM
Poster Session 2
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Monday, March 30 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky Ballroom A, Lower Level


Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
Room: Sea to Sky Ballroom B

Speaker 1 of 7
* Louis M. Weiner, Georgetown University Medical Center, USA

Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
Room: Sea to Sky Ballroom B

Speaker 2 of 7
Mark X. Sliwkowski, Genentech, Inc., USA
HER2 Targeted Therapies

Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
Room: Sea to Sky Ballroom B

Speaker 3 of 7
Andrew M. Scott, Ludwig Institute for Cancer Research, Australia
Targeting a Novel EGFR Epitope on Cancer Cells

Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
Room: Sea to Sky Ballroom B

Speaker 4 of 7
Kerry A. Chester, University College London Cancer Institute, UK
Antibody-Directed Enzyme Prodrug Therapy (ADEPT) of Cancer

Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
Room: Sea to Sky Ballroom B

Speaker 5 of 7
Philip E. Thorpe, University of Texas Southwestern Medical Center, USA
Targeting Exposed Phosphatidylserine on Cancer Blood Vessels: Preclinical and Clinical Studies

Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
Room: Sea to Sky Ballroom B

Speaker 6 of 7
Kelly J. Davis, Massachusetts Institute of Technology, USA
Short Talk: Antibody with Picomolar Affinity to DOTA Chelates of Multiple Radionuclides for Pretargeted Radioimmunotherapy

Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
Room: Sea to Sky Ballroom B

Speaker 7 of 7
Mitsuo Satoh, Research Division, Kyowa Hakko Kirin Company Ltd., Japan
Short Talk: Non-Fucosylated Rituximab Potentiates Human Neutrophil Phagocytosis through its High Binding for FcgammaRIIIb and MHC Class II Expression on the Phagocytotic Neutrophils

Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 1 of 7
* D. Gary Gilliland, Merck & Co., Inc., USA


Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 2 of 7
Alan Ashworth, University of California, San Francisco, USA
Synthetic Lethal Approaches to the Development of New Therapies Targeting DNA Repair Deficiencies in Cancer


Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 3 of 7
William G. Kaelin, Jr., Dana-Farber Cancer Institute, USA
Therapeutic Targets Emerging from Studies of the VHL Tumor Suppressor Protein and 2-Oxoglutarate Dependent Dioxygenases


Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 4 of 7
Peter A. Jones, Van Andel Research Institute, USA
Epigenetic Therapy


Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 5 of 7
Lynda Chin, University of Texas MD Anderson Cancer Center, USA
Mining and Translating the Cancer Genome


Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 6 of 7
Igor Landais, Oregon Health Sciences University, USA
Short Talk: Identification of Potent Inhibitors of the Fanconi Anemia Pathway Using a Novel Cell-Free Assay


Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
This session is from Targeted Cancer Therapies
Room: Sea to Sky Ballroom C

Speaker 7 of 7
Johannes Zuber, Research Institute of Molecular Pathology, Austria
Short Talk: In-vivo Evaluation of Putative Drug Targets in Chemotherapy-Resistant MLL/AF9-Induced Acute Myeloid Leukemia Using Tet-Regulatable RNAi


Monday, March 30 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Monday, March 30 | 11:15AM - 1:00PM
Poster Setup
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Monday, March 30 | 11:15AM - 11:15AM
On Own for Lunch


Monday, March 30 | 1:00PM - 10:00PM
Poster Viewing
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Monday, March 30 | 2:30PM - 4:30PM
Workshop 3: Therapeutic Antibodies in the Neurosciences
Room: Sea to Sky Ballroom B

Speaker 1 of 4
* Eric V. Shusta, University of Wisconsin-Madison, USA
Antibodies and the Blood-Brain Barrier

Monday, March 30 | 2:30PM - 4:30PM
Workshop 3: Therapeutic Antibodies in the Neurosciences
Room: Sea to Sky Ballroom B

Speaker 2 of 4
Anne Messer, Wadsworth Center, USA
Intrabodies for Neurodegeneration Disorders

Monday, March 30 | 2:30PM - 4:30PM
Workshop 3: Therapeutic Antibodies in the Neurosciences
Room: Sea to Sky Ballroom B

Speaker 3 of 4
Anthony Williamson, Calmune Corporation, USA
Antibodies for Prion Based Diseases

Monday, March 30 | 2:30PM - 4:30PM
Workshop 3: Therapeutic Antibodies in the Neurosciences
Room: Sea to Sky Ballroom B

Speaker 4 of 4
Angela R. Jones, University of Wisconsin - Madison, USA
Short Talk: Identification of Blood-Brain Barrier Targeting and Transporting Antibodies

Monday, March 30 | 4:30PM - 5:00PM
Coffee Available
Room: Foyer


No content found

No content found

No content found